Merck & Co. Inc.

MRK | NYSE

Price Alert Chart Builder DCF Calculator

$148.06

+$1.19 (+0.81%)

Sep 21, 2026, 10:24 AM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Dividends Profile

+0.81%

(1D)

Rating

Updated: Sep 19, 2026

44.5

Fundamentals Average

Market Sentiment Neutral

Moat Wide

Full Analysis

Why Price Moved

11 days ago

-1.91%

Merck shares declined as the company outlined its ...

Key Statistics

Market Data

Market Cap $365.69B

1D Range

145.61 149.13

52W Range

77.58 156.92

Valuation (TTM)

PE 117.41

PB 8.64

EV/EBITDA 34.14

Valuation (NTM)

Forward PE 15.40

Forward PEG 0.47

Price Target $158.12

Cash Flow

FCF Yield 4.4%

SBC Adj. FCF Yield 4.2%

SBC Impact -5.5%

Margins

Gross Margin 75.4%

Operating Margin 17.0%

FCF Margin 24.2%

Growth (CAGR)

Revenue 3Y | 5Y 4.4% | 7.9%

Dil EPS 3Y | 5Y 0.8% | -10.7%

FCF 3Y | 5Y 14.1% | 23.6%

Returns

ROA 2.4%

ROE 6.6%

ROIC 5.6%

Financial Health

Net Debt

$46.77B

Current Ratio 1.32

Interest Coverage 8.75

Dividends

Div Yield 2.32%

Payout Ratio 272.0%

FCF Payout Ratio 51.7%

All Key Statistics

Loading financial charts...

Profile

Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broa...

Sector Healthcare

Industry Drug Manufacturers - General

Employees 74,000

IPO Date Jan 12, 1978

Website www.merck.com

Fiscal Year January - December

Full Company Profile

Latest News

7 hours ago · businesswire.com

Merck's KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Approved in Japan for Subcutaneous Administration for All KEYTRUDA® (pembrolizumab) Indications Approved in Japan

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the Ministry of Health, Labor and Welfare (MHLW) in Japan has approved KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) injection for subcutaneous use for all indications approved in Japan for KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy. In Japan, KEYJECT®, for subcutaneous injection is the planned trademark for KEYTRUDA QLEX. KEYJECT can be administered.

3 days ago · businesswire.com

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC)

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval of KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with Padcev® (enfortumab vedotin-ejfv), as neoadjuvant treatment and then continued after radical cystectomy as adjuvant treatment for adults with resectable muscle-invasiv.

3 days ago · zacks.com

Merck (MRK) Outperforms Broader Market: What You Need to Know

Merck (MRK) closed at $147.17 in the latest trading session, marking a +1.56% move from the prior day.

6 days ago · marketbeat.com

Merck CEO Sees Pipeline Upside as Launches, Animal Health Drive Transformation

Merck & Co., Inc. NYSE: MRK Chairman and CEO Rob Davis said the company's “transformation is underway,” citing progress across product launches, clinical data readouts, business development and its Animal Health segment during a Morgan Stanley discussion.

6 days ago · seekingalpha.com

Merck & Co., Inc. (MRK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

7 days ago · globenewswire.com

Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid Tumors

SEATTLE, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced a clinical trial collaboration agreement with Merck (NYSE: MRK), known as MSD outside of the United States and Canada.

10 days ago · zacks.com

MRK Banks on Growing Pipeline & New Drugs to Offset Keytruda LOE

Merck is expanding its pipeline and newer drug portfolio to offset Keytruda's 2028 LOE and drive long-term growth.

11 days ago · benzinga.com

Congresswoman Bets on Elon Musk, Warren Buffett: Here's the Latest Stock Transactions

Retail investors often monitor the trading activity of members of Congress. Investors may want to pay particular attention to recent trades from one member, with stocks connected to Elon Musk and Warren Buffett among the bets.